Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Acceleron Pharma
Pharma
Merck is axing 143 Acceleron positions after buyout
Merck & Co.'s $11.5 Acceleron Pharma buyout was one of the largest M&A deals of 2021—and it was also among the most contentious.
Fraiser Kansteiner
Mar 30, 2022 9:50am
The FDA delayed its decision date on a new nod for BMS' Reblozyl
Mar 25, 2022 9:55am
Top 10 biopharma M&A deals in 2021
Jan 18, 2022 3:00am
Merck fights off Acceleron's activist investors
Nov 22, 2021 9:05am
Another Acceleron investor challenges Merck deal
Nov 3, 2021 12:03pm
Merck refiles Acceleron deal with the FTC
Nov 1, 2021 11:59am
